Finance

Lists
Why is MCRB down 5,17%?
Dive Deeper
MCRB:NASDAQ
Seres Therapeutics Inc
USD 2,75
-5,17%
(-0,15) 1D
7 Okt., 12:08:44 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
USD 2,86
High
USD 3,00
Low
USD 2,73
Mkt. cap
27,34 m
Avg. vol.
65,19 k
Volume
36,37 k
52-wk high
USD 29,98
52-wk low
USD 2,73
EPS
-USD 2,33
Beta
0,31
Shares outstanding
9,94 m
No. of employees
66
Open
USD 2,86
High
USD 3,00
Low
USD 2,73
Mkt. cap
27,34 m
Avg. vol.
65,19 k
Volume
36,37 k
52-wk high
USD 29,98
52-wk low
USD 2,73
EPS
-USD 2,33
Beta
0,31
Shares outstanding
9,94 m
No. of employees
66
News stories
From web sources and news partners
About Seres Therapeutics Inc
CEOEric Shaff
Employees66
Founded2010
Headquarters-
Sector-
Websiteserestherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current USD 2,75
USD 22,00 (+700,00%)
Average
USD 17,00 (+518,18%)
Lowest
USD 12,00 (+336,36%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
USD 22,00
+700%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
USD 12,00
+336,4%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
USD 20,00
+627,3%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
05 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 1,07 / -USD 2,30
+146,33%beat
Revenue / Est. (USD)
736,00 k / 358,00 k
+105,59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
351,00 k
438,00 k
358,00 k
736,00 k
Cost of goods sold
13,35 m
12,28 m
13,20 m
9,14 m
Cost of revenue
13,35 m
12,28 m
13,20 m
9,14 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,48 m
7,54 m
8,07 m
7,06 m
Operating expense
9,48 m
7,54 m
8,07 m
7,06 m
Total operating expenses
22,83 m
19,82 m
21,26 m
16,20 m
Operating income
-22,48 m
-19,38 m
-20,91 m
-15,47 m
Other non operating income
2,84 m
2,33 m
669,00 k
673,00 k
EBT including unusual items
8,20 m
-15,34 m
-19,91 m
4,58 m
EBT excluding unusual items
-19,02 m
-16,60 m
-19,91 m
-14,61 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
8,20 m
-15,34 m
-19,91 m
4,58 m
Net profit margin
2 337,32%
-3 501,14%
-5 562,29%
622,42%
Earnings per share
0,94
-1,76
-2,08
1,07
Interest and investment income
618,00 k
445,00 k
325,00 k
181,00 k
Interest expense
-
-
-
-
Net interest expenses
618,00 k
445,00 k
325,00 k
181,00 k
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,43 m
-18,42 m
-20,13 m
-14,80 m
Gain or loss from assets sale
-
-192,00 k
-
139,00 k
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme